Tcelna® (imilecleucel-T) Opexa Therapeutics, 2013 Accessed on 24 Sep 2013 from http://www.opexatherapeutics.com/tcelna/tcelna-description/default.aspx.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Loftus B, Newsom B, Montgomery M, Von Gynz-Rekowski K, Riser M, Inman S, Garces P, Rill D, Zhang J, Williams JC Clin Immunol. 2009 May; 131(2):202-15. Epub 2009 Feb 18. PMID: 19230777. Abstract
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (DES) ClinicalTrials.gov, 27 Jun 2011 Accessed on 24 Sep 2013 from http://www.clinicaltrials.gov/ct2/show/NCT00587691.
T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Hellings N, Raus J, Stinissen P Autoimmun Rev. 2004 Jun; 3(4):267-75. PMID: 15246022. Abstract
MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Zhang J, Medaer R, Stinissen P, Hafler D, Raus J Science. 1993 Sep 10; 261(5127):1451-4. PMID: 7690157. Abstract
Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. Hermans G, Denzer U, Lohse A, Raus J, Stinissen P J Autoimmun. 1999 Sep; 13(2):233-46. PMID: 10479392. Abstract
In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. Zhang J, Vandevyver C, Stinissen P, Raus J J Immunol. 1995 Dec 15; 155(12):5868-77. PMID: 7499877. Abstract
Human CD8+ TCR-alpha beta(+) and TCR-gamma delta(+) cells modulate autologous autoreactive neuroantigen-specific CD4+ T-cells by different mechanisms. Correale J, Rojany M, Weiner LP J Neuroimmunol. 1997 Dec; 80(1-2):47-64. PMID: 9413259. Abstract
Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Lider O, Reshef T, Beraud E, Ben-Nun A, Cohen IR Science. 1988 Jan 8; 239(4836):181-3. PMID: 2447648. Abstract
Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Lohse AW, Mor F, Karin N, Cohen IR Science. 1989 May 19; 244(4906):820-2. PMID: 2471264. Abstract
Humoral mechanisms in T cell vaccination: induction and functional characterization of anti-lymphocytic autoantibodies. Herkel J, Brunner S, Meyer zum Büschenfelde KH, Lohse AW J Autoimmun. 1997 Apr; 10(2):137-46. PMID: 9185875. Abstract
Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Ben-Nun A, Wekerle H, Cohen IR Nature. 1981 Jul 2; 292(5818):60-1. PMID: 6974307. Abstract
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (Abili-T) ClinicalTrials.gov, 28 Aug 2013 Accessed on 27 Sep 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01684761.
Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis. van Laar JM, Miltenburg AM, Verdonk MJ, Leow A, Elferink BG, Daha MR, Cohen IR, de Vries RR, Breedveld FC J Autoimmun. 1993 Apr; 6(2):159-67. PMID: 8098938. Abstract
T-cell vaccination in Crohn's disease: principles and presentation of the first two cases. Agnholt J, Kaltoft K, Jakobsen NO, Dahlerup JF Cytokines Cell Mol Ther. 2002; 7(3):117-23. PMID: 12850811. Abstract
Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR Proc Natl Acad Sci U S A. 1991 Apr 15; 88(8):3088-91. PMID: 1707531. Abstract
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination. Beraud E, Kotake S, Caspi RR, Oddo SM, Chan CC, Gery I, Nussenblatt RB Cell Immunol. 1992 Mar; 140(1):112-22. PMID: 1739982. Abstract
Prolongation of survival of rat cardiac allografts by T cell vaccination. Shapira OM, Mor E, Reshef T, Pfeffermann RA, Cohen IR J Clin Invest. 1993 Feb; 91(2):388-90. PMID: 8432846. Abstract
Opexa's Tovaxin® for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA Opexa Therapeutics, 8 Nov 2011 Accessed on 27 Sep 2013 from http://www.opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2011/Opexas-Tovaxin-for-the-Treatment-of-Multiple-Sclerosis-Granted-Fast-Track-Designation-by-FDA/default.aspx.
Opexa Therapeutics Announces Tcelna™ as New Brand Name for MS Therapy Opexa Therapeutics, 21 May 2012 Accessed on 27 Sep 2013 from http://www.opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2012/Opexa-Therapeutics-Announces-Tcelna-as-New-Brand-Name-for-MS-Therapy/default.aspx.
Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis Opexa Therapeutics, 5 Feb 2013 Accessed on 27 Sep 2013 from http://www.opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Merck-Serono-and-Opexa-Therapeutics-Enter-into-Option-and-License-Agreement-for-Development-of-Tcelna-imilecleucel-T-for-Treatment-of-Multiple-Sclerosis/default.
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Fox E, Wynn D, Cohan S, Rill D, McGuire D, Markowitz C Mult Scler. 2012 Jun; 18(6):843-52. Epub 2011 Nov 06. PMID: 22065170. Abstract
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS) ClinicalTrials.gov, 27 Jun 2011 Accessed on 27 Sep 2013 from http://www.clinicaltrials.gov/ct2/show/NCT00245622.
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis (OLTERMS) ClinicalTrials.gov, 9 Oct 2012 Accessed on 27 Sep 2013 from http://www.clinicaltrials.gov/ct2/show/NCT00595920.
T cell vaccination in multiple sclerosis: results of a preliminary study. Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, Haykal H, Killian J, Zang YCQ J Neurol. 2002 Feb; 249(2):212-8. PMID: 11985389. Abstract
Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J Lancet. 1995 Sep 23; 346(8978):807-8. PMID: 7545769. Abstract
Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. Hermans G, Medaer R, Raus J, Stinissen P J Neuroimmunol. 2000 Jan 3; 102(1):79-84. PMID: 10626670. Abstract
Opexa Therapeutics reports third quarter 2013 financial results and provides corporate update Opexa Therapeutics, 7 Nov 2013 Accessed on 10 Nov 2013 from http://www.opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Opexa-Therapeutics-Reports-Third-Quarter-2013-Financial-Results-and-Provides-Corporate-Update/default.aspx.
Opexa Therapeutics provides MS trial enrollment update; 70% of patients enrolled Opexa Therapeutics, 16 Dec 2013 Accessed on 30 Dec 2013 from http://www.opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Provides-MS-Trial-Enrollment-Update-70-of-Patients-Enrolled/default.aspx.
Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis Opexa Therapeutics, 13 May 2014 Accessed on 17 May 2014 from http://www.opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2014/Opexa-Reaches-Enrollment-Target-in-Phase-IIb-Trial-of-Personalized-Immunotherapy-for-Secondary-Progressive-Multiple-Sclerosis/default.aspx.
Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis Opexa Therapeutics, 9 Mar 2015 Accessed on 10 Mar 2015 from http://www.opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Amends-Agreement-with-Merck-Serono-and-Receives-Additional-3-Million-Payment-to-Support-Ongoing-Development-of-Tcelna-for-Multiple-Sclerosis/default.aspx.
